| 23rd week of 2011 patent applcation highlights part 51 |
| Patent application number | Title | Published |
|---|
| 20110136694 | DENSITY MODIFICATION IN ARRAYS OF SURFACE-ATTACHED NUCLEIC ACID MOLECULES - Substrates having nucleic acid polymers attached at varying surface densities and methods for creating substrates having nucleic acid polymers attached at varying surface densities are provided. Methods according to embodiments of the invention are adapted to the rapid synthesis of arrays of DNA polymers on a substrate surface. In embodiments of the invention an array of DNA molecules on a substrate comprises a plurality of DNA polymers attached to a trifunctional linker such that at least two DNA polymers are attached to one trifunctional linker that is attached to the surface of the substrate. By coupling trifunctional linkers to trifunctional linkers that are attached to a substrate surface, the density of DNA polymers on a substrate surface is increased. | 2011-06-09 |
| 20110136695 | UNIVERSAL LIBRARIES FOR IMMUNOGLOBULIN - Libraries of immunoglobulins of interest are described, the libraries containing mutated immunoglobulins of interest in which a single predetermined amino acid has been substituted in one or more positions in one or more complementarity-determining regions of the immunoglobulin of interest. The libraries comprise a series of subset libraries, in which the predetermined amino acid is “walked through” each of the six complementarity-determining regions (CDRs) of the immunoglobulin of interest not only individually but also for each of the possible combinatorial variations of the CDRs, resulting in subset libraries that include mutated immunoglobulins having the predetermined amino acid at one or more positions in each CDR, and collectively having the predetermined amino acid at each position in each CDR. The invention is further drawn to universal libraries containing one such library for each naturally-occurring amino acid as the single predetermined amino acid, totaling twenty libraries; and also to libraries of nucleic acids encoding the described libraries. | 2011-06-09 |
| 20110136696 | CONTINUOUS POLYMER SYNTHESIZER - Described is a system and method for synthesizing polymeric molecules such as oligonucleotides and polypeptides. The system is capable of continuously synthesizing molecules by providing an array of reaction sites and an array of stations for carrying out synthetic manipulations. The reaction sites in the former array can be placed in a fixed order and at fixed intervals relative to each other. Similarly, the stations can be placed in a fixed order and at fixed intervals relative to each other. The two arrays can be moved relative to each other such that the stations carry out desired steps of a reaction scheme at each reaction site. The relative locations of the stations and the schedule for the relative movement can correlate with the order and duration of reaction steps in the reaction scheme such that once a reaction site has completed a cycle of interacting with the full array of stations then the reaction scheme is complete. | 2011-06-09 |
| 20110136697 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES - The present invention provides a method of synthesizing libraries of molecules which include an encoding oligonucleotide tag. | 2011-06-09 |
| 20110136698 | Chip with tri-layer electrode and micro-cavity arrays for control of bioparticle and manufacturing method thereof - A chip with tri-layer electrodes and micro-cavity arrays for control of bioparticles and a manufacturing method thereof are revealed. The chip captures and releases bioparticles into and from preset cavities by dielectrophoresis (DEP) force generated by electrodes. The chip includes an upper layer body, a middle layer body, a lower layer body, respectively disposed with an electrode, and micro flow chambers. The electrodes of the upper layer body and the middle layer body are common electrodes while the electrode of the lower layer body is a dispersive electrode array exposed on the bottom of lower-layer microcavity. The cell capture and release at the single-cell level and the cell population level are attained by application of an AC electric field. | 2011-06-09 |
| 20110136699 | MANUFACTURING AND PROCESSING POLYMER ARRAYS - The invention provides methods to process multiple microarrays by providing a microarray plate and processing plates. In an embodiment of the invention, methods for assembling microarray plates by using wafers are described for high throughput microarray processing. | 2011-06-09 |
| 20110136700 | Method and System for Preventing Clathrate Hydrate Blockage Formation in Flow Lines by Enhancing Water Cut - The present invention includes a method for inhibiting hydrate formation blockage in a flow line used to transport hydrocarbon containing fluids. Water is added to a hydrocarbon containing fluid to produce a water cut enhanced hydrocarbon containing fluid. Salt may be added to the hydrocarbon containing fluids as well. Hydrate formation blockage is inhibited from forming within the flow line by the addition of the water and/or the salt. Sufficient water may be added such that the hydrocarbon containing fluid is converted from a water in oil emulsion to a water continuous emulsion. A system for preventing the formation of hydrate blockage in conduits is also provided. The system includes a flow line for transporting a hydrocarbon containing fluid and a water injection conduit fluidly connected to the flow line to add water to the flow line to increase the water cut of a hydrocarbon containing fluid flowing through the flow line. A salt dispenser may also be included which is used to increase the salinity of the hydrocarbon containing fluid. The system may further include a water separator to separate hydrocarbons from water which receives fluids from the flow line. The flow line, water separator and water injection conduit may cooperate to form a loop wherein water from the flow line may be separated by the water separator and a portion of the separated water is delivered back to the water injection conduit to be reinjected into the flow line. | 2011-06-09 |
| 20110136701 | HIGH PERFORMANCE WATER BASED FLUIDS - A water based wellbore fluid that includes an aqueous fluid; a micronized weighting agent; a polysaccharide derivative; and at least one fatty acid ester derivative is disclosed. | 2011-06-09 |
| 20110136702 | Wellbore Fluid Additives and Methods of Producing the Same - Disclosed herein is a polymer useful in a method of forming a wellbore fluid additive. This polymer comprises a polyethylene backbone comprising pendant aminoalkylsulfonic acid amides which comprise a carbonyl directly attached to a backbone carbon, and an amide formed via the amine group from the aminoalkylsulfonic acid. Methods of preparing these polymers by addition of the aminoalkylsulfonic acid to a polymeric anhydride are disclosed. Methods related to oil extraction using the wellbore fluid with the additive are also disclosed. | 2011-06-09 |
| 20110136703 | Compositions for Stimulating Liquid-Sensitive Subterranean Formations - A method comprising: A subterranean formation stimulation fluid comprising a stimulation gas and a consolidating agent. Suitable consolidating agents include aqueous tackifying agents, curable compositions, and noncurable and nonaqueous consolidating compositions. | 2011-06-09 |
| 20110136704 | Methods of Treating a Hydrocarbon-Bearing Formation, a Well Bore, and Particles - Methods of treating articles using a compound represented by formula: (I) wherein each of X and Y is independently a thiol, a halogen, a hydrogen, a hydroxyl, a hydroalkyl, a carboxylic acid, an aldehyde, a carboxylic ester, or a carboxamide; R′ is hydrogen, alkyl, or aryl; and x and y are each independently 0 to 10, wherein x+y is at least 1 and articles treated by such methods. In some embodiments, the article is a hydrocarbon-bearing formation. In some embodiments, the article is a particle, and the method further comprises treating the article with a fluorochemical comprising at least one fluoroaliphatic segment and at least one hydrophilic segment. In some embodiments, the method is used to treat a well bore. | 2011-06-09 |
| 20110136705 | PHOSPHATE ESTER OIL GELLANT - A composition and method of fracturing a subterranean formation. The composition includes: about 0.25 wt. % to about 3.0 wt. %, based on a weight of the hydrocarbon liquid, of a mixture of phosphate esters, said esters selected from the group consisting of: monoester PO(OR | 2011-06-09 |
| 20110136706 | ORGANOSULFONYL LATENT ACIDS FOR PETROLEUM WELL ACIDIZING - Oil wells are treated with latent acids containing a sulfonyl moiety, wherein the latent acid is capable of providing an active acid after injection into an oil well. The latent acids are converted to active acids such as mineral acids or strong organic acids in the oil well, with resultant dissolution of acid-soluble minerals that impede oil or gas flow. Exemplary latent acids are according to any of formulas (I), (II), and (III) | 2011-06-09 |
| 20110136707 | ENGINEERED POWDER COMPACT COMPOSITE MATERIAL - An engineered dispersed particle-cellular nanomatrix composite material is disclosed. The engineered dispersed particle-cellular nanomatrix composite material is configured for contact with a fluid and configured to provide a selectable and controllable transition from one of a first strength condition to a second strength condition that is lower than a functional strength threshold, or a first weight loss amount to a second weight loss amount that is greater than a weight loss limit, as a function of a time in contact with the fluid. | 2011-06-09 |
| 20110136708 | GREASE COMPOSITION - There is provided a grease composition, including: a base oil; a metal soap thickener formed of at least one metal selected from the group consisting of lithium, calcium, magnesium and aluminum and a fatty acid containing at least one selected from the group consisting of a hydroxyl group, a carboxyl group and a carboxylic acid metal salt group in each molecular structure; and nanoparticles formed of at least one selected from the group consisting of oxides, carbides and diamond materials. | 2011-06-09 |
| 20110136709 | GREASE COMPOSITION - Grease composition for use in resin lubrication incorporating into a grease base material which includes a base oil and a fatty acid metal salt thickener at least one saturated or unsaturated fatty acid having from 8 to 22 carbon atoms and/or fatty acid metal salt, being a metal salt of a linear saturated fatty acid having from 8 to 14 carbon atoms or a metal salt of an unsaturated fatty acid having from 16 to 22 carbon atoms and from 1 to 4 unsaturated groups, the metal having a valence of from 1 to 4 excluding fatty acid metal salts used for the thickener. The grease composition of the present invention gives satisfactory lubrication properties between resin and resin or resin and other material such as a metal. | 2011-06-09 |
| 20110136710 | AMINOMETHYL- SUBSTITUTED IMIDAZOLE COMPOUNDS FOR USE AS FRICTION MODIFIERS IN LUBRICATING OIL COMPOSITIONS - Disclosed are aminomethyl-substituted imidazole compounds and their use as friction modifiers in lubricating oils. Also disclosed is a process for preparing the aminomethyl-substituted imidazole compounds. A further aspect is directed to a lubricating oil composition and a lubricating oil additive concentrate having the aminomethyl-substituted imidazole compounds of the present invention. | 2011-06-09 |
| 20110136711 | HIGHLY OVERBASED MAGNESIUM ALKYTOLUENE SULFONATES - A process for preparing a highly overbased magnesium alkyltoluene sulfonates comprising: (A) reacting at least one oil soluble alkyltoluene sulfonic acid and at least one source of magnesium, in the presence of a mixture comprising: (i) at least one hydrocarbon solvent; and (ii) at least one low molecular weight alcohol; (B) contacting the reaction product of (A) with at least one promoter and water; (C) contacting the product of (B) with an overbasing acid; and (D) heating the reaction product of (C) to a temperature greater than the distillation temperature of the hydrocarbon solvent, the low molecular weight alcohol, and the water to distill the hydrocarbon solvent, the low molecular weight alcohol, and the water. | 2011-06-09 |
| 20110136712 | PROCESS FOR LUBRICATING A REFRIGERATOR CONTAINING SLIDING PARTS MADE OF AN ENGINEERING PLASTIC MATERIAL - A process to lubricate a refrigerator preferably having a sliding portion which is made of an engineering plastic material, or provided thereon with an organic coating film or an inorganic coating film is provided. The process includes contacting sliding parts of the refrigerator with a refrigerating machine oil composition having a base oil containing a polyvinyl ether and/or a polyoxyalkylene glycol derivative as a main component and having a kinematic viscosity of 1 to 8 mm | 2011-06-09 |
| 20110136713 | Hydrofluoroalcohols with improved thermal and chemical stability - Hydrofluoro alcohols of formula (I): A—(R | 2011-06-09 |
| 20110136714 | High Viscosity Novel Base Stock Lubricant Viscosity Blends - A lubricant formulation and method of blending a lubricant formulation is disclosed. The lubricant formulation comprises at least two base stocks. The first base stock comprises a viscosity greater than 135 cSt, Kv100° C. and a tight molecular weight distribution as a function of viscosity. The second base stock comprises a viscosity less than 60 cSt, Kv100° C. The formulation also comprises a polyol ester. The lubricant formulation provides favorable properties. | 2011-06-09 |
| 20110136715 | COLOR-CHANGING PRE-TREATMENT STAIN REMOVERS AND METHODS FOR FABRICATING THE SAME - Color-changing pre-treatment stain removers and methods for fabricating them are provided. In one embodiment, a color-changing pre-treatment stain remover comprises a stain remover composition and a colorant that changes color upon contact with a stain on a textile within a time period that the stain is pre-treated by the stain remover composition. A method for fabricating a color-changing pre-treatment stain remover comprises forming a stain remover composition and adding a colorant to the stain remover composition. The colorant is adapted to change color upon contact with a stain on a textile within a time period that the stain is treated by the stain remover composition. The stain remover composition and the colorant are mixed until a homogeneous mixture is achieved. | 2011-06-09 |
| 20110136716 | NOVEL METHOD FOR IMPROVING THE FOAMING PROPERTIES OF CLEANSING AND/OR FOAMING FORMULATIONS FOR TOPICAL USE - Methods for improving the foaming properties of cleansing and foaming formulations for topical use are presented. The methods comprise including in the formulation an effective amount of a polyol glycoside or a mixture of polyol glycosides of formula (I) R | 2011-06-09 |
| 20110136717 | Formulations And Method For Post-CMP Cleaning - The present invention is a method of cleaning to removal residue in semiconductor manufacturing processing, comprising contacting a surface to be cleaned with an aqueous formulation having a polymer selected from the group consisting of acrylamido-methyl-propane sulfonate) polymers, acrylic acid-2-acrylamido-2-methylpropane sulfonic acid copolymer and mixtures thereof and a quaternary ammonium hydroxide having greater than 4 carbon atoms or choline hydroxide with a non-acetylinic surfactant. | 2011-06-09 |
| 20110136718 | HYBRID COPOLYMERS - Hybrid copolymers for use as anti-scalant and dispersant. The polymers are useful in compositions used in aqueous systems. The polymers include at least one synthetic monomeric constituent that is chain terminated by a naturally occurring hydroxyl containing moiety. A process for preparing these hybrid copolymers is also provided. | 2011-06-09 |
| 20110136719 | Dissolvable laundry detergent sheet - A flexible laundry sheet made of a mixture of at least a thickening agent, detergent, water and polyvinyl alcohol. The thickening agent is comprised of polymers such as starch, modified starch, or cellulose that, when dried, produce a material that remains solid and flexible when dry, yet dissolves completely in water. The constituents, once mixed in the proper proportion, produce a liquid that is poured onto a drying plate, and after drying results in a flexible, dry, laundry sheet which may be added to laundry. Once in contact with water the laundry sheet dissolves and releases its active ingredients, which may include detergents, surfactants, water softeners, chelating agents, dyes, fragrances, clothes softeners and bleaching agents. | 2011-06-09 |
| 20110136720 | METHOD FOR IMPROVING THE CLEANING ACTION OF A DETERGENT OR CLEANING AGENT - A washing or cleaning process includes the step of preparing a washing or cleaning solution that includes a washing or cleaning agent including a hydrolytic enzyme, and a component that, by interacting with the hydrolytic enzyme when the agent is used, affects a synergistic cleaning power. The component may be an anionic and/or polyanionic substance, a cationic and/or polycationic substance, and/or a substance that possesses hydroxyl and/or polyhydroxyl group(s). The process then includes the step of contacting a textile or a hard surface with the washing or cleaning solution. | 2011-06-09 |
| 20110136721 | Pearlescent Agent Slurry for Liquid Treatment Composition - An inorganic pearlescent agent slurry for use in liquid treatment compositions. The slurry comprises: inorganic pearlescent agent; organic solvent, selected from the group consisting of glycerol, sorbitol and mixtures thereof; and rheology modifier. The inorganic pearlescent agent may be selected from the group consisting of mica, bismuth oxychloride, and mixtures thereof. | 2011-06-09 |
| 20110136722 | Drug Delivery Carrier - The present disclosure relates to a method for the sustained release of a drug, comprising the steps of: (a) preparing a biocompatible polymer having a hydrophobic group conjugated to the biocompatible polymer; and (b) contacting the biocompatible polymer to the drug for adsorbing the drug to the hydrophobic group of the biocompatible polymer, thereby obtaining a drug delivery carrier for the sustained release of the drug; wherein the drug is a protein, a peptide or a non-hydrophilic chemical drug; wherein when the drug adsorbed to the hydrophobic group of the biocompatible polymer is administered to a mammal, it shows a sustained release profile in the mammal. The drug delivery carrier according to the present disclosure having the hydrophobic group conjugated to the biocompatible polymer may be useful for adsorption of synthetic drugs having very low solubility in water. Further, it may regulate discharge rate of adsorbed drugs by regulating a portion of hydrophobic groups conjugated to the polymeric material. Thus, the present disclosure provides a broad-spectrum platform technology applicable to new hydrophobic synthetic drugs to be developed in the future as well as those that have been developed already but face difficulties due to low bioavailability. | 2011-06-09 |
| 20110136723 | NOVEL REAGENTS AND METHOD FOR CONJUGATING BIOLOGICAL MOLECULES - A compound of the general formula X-[Q-W—(CH═CH) | 2011-06-09 |
| 20110136724 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE - There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity. | 2011-06-09 |
| 20110136725 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL - There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity. | 2011-06-09 |
| 20110136726 | NOVEL ANTIMICROBIAL AGENTS - A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same. | 2011-06-09 |
| 20110136727 | Compositions and methods for rapid selection of pathogen binding agents - Isolated glycan binding peptide complex comprise two or more glycan binding peptides operatively coupled to each other. These are bacterial binding peptide conjugates (e.g., glycan binding peptides) to a multivalent polymer (e.g., a multivalent PEG molecule) or to the surface of particles that create multimeric constructs that inhibit growth and aggregation of microbes. Included is a method of evaluating a substance for the presence of a microbe comprising contacting the substance with a peptide microarray or a peptide complex comprising a plurality glycan binding peptide operatively coupled to a substrate or multivalent linker, wherein the glycan binding peptide is coupled to an array by a linker that is at least 0.5 micrometers in length. | 2011-06-09 |
| 20110136728 | METHODS OF INCREASING BONE FORMATION USING LEPTIN-RELATED PEPTIDES - The present invention relates to methods of increasing bone formation in patient suffering from a wasting disorder by orally or intranasally administering a pharmaceutically effective amount of a leptin peptide and a pharmaceutically acceptable carrier, wherein the leptin peptide increases serum osteocalcin levels. | 2011-06-09 |
| 20110136729 | Occidiofungin, a unique antifungal glycopeptide produced by a strain of burkholderia contaminans - The present invention is directed to novel antifungal glycopeptide compounds and salts thereof produced by a strain of | 2011-06-09 |
| 20110136730 | "Method for screening compounds comprising the use of picornavirus protease 2A" - A method of screening compounds or molecules comprising the steps of: translating a sequence encoding the amino acid sequence comprising SEQ ID No. 29 in a translation system in the presence of a test compound or molecule; and analysing the translation product(s) for the presence of one or more of (a) a peptide comprising the amino acids Pro-Gly at the C terminus and a peptide comprising the amino acid Pro at the N terminus: or (b) a peptide comprising the amino acid sequence of SEQ ID No. 29. | 2011-06-09 |
| 20110136731 | PROTEIN HAVING PESTICIDAL ACTIVITY, DNA ENCODING THE PROTEIN, AND NOXIOUS ORGANISM-CONTROLLING AGENT THAT CONTROLS THE INSECT PEST, EMERALD ASH BORER (EAB), AGRILUS PLANIPENNIS - A noxious organism-controlling agent disclosed herein is effective to pests that have acquired a resistance to conventional | 2011-06-09 |
| 20110136732 | INFANT NUTRITIONAL COMPOSITIONS FOR PREVENTING OBESITY - The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant with the age between 0 and 36 months. The composition comprises linoleic acid and alpha-linolenic acid. | 2011-06-09 |
| 20110136733 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE - There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity. | 2011-06-09 |
| 20110136734 | Methods of Modulating Inflammation in Preterm Infants Using Carotenoids - The present disclosure relates to preterm infant formulas comprising lutein, lycopene, and beta-carotene, and the use of the preterm infant formulas to modulate inflammation, such as skin inflammation, in preterm infants. Also disclosed are methods of modulating the level of C-reactive protein in a preterm infant using preterm infant formulas comprising mixtures of carotenoids. | 2011-06-09 |
| 20110136735 | CYCLOHEXANE DERIVATIVES AND USES THEREOF - The present invention provides a compound of formula I; | 2011-06-09 |
| 20110136736 | NEW INSULIN ANALOGUES OF PROLONGED ACTIVITY - New biosynthetic analogues of recombined human insulin of prolonged therapeutical activity, which can find place in prophylactic and treatment of diabetes. | 2011-06-09 |
| 20110136737 | DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties - The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 2011-06-09 |
| 20110136738 | Alternatively Transcribed Genes Associated with Schizophrenia - Methods of identifying gene targets associated with schizophrenia or the symptoms thereof, as well as to specific nucleic acid molecules that have been discovered to be associated with schizophrenia are provided. Accordingly, the invention also relates to methods of modulating schizophrenia or the symptoms thereof, methods of diagnosing schizophrenia or the symptoms thereof, methods for predicting the susceptibility to schizophrenia or the symptoms thereof, and methods of identifying compounds that modulate schizophrenia or the symptoms thereof via manipulations of the nucleic acid molecules and their products. | 2011-06-09 |
| 20110136739 | Use of S1P Receptor Agonists in Heart Diseases - The invention relates to the use of sphingosine-1-phosphate receptor agonist in the treatment of heart diseases. | 2011-06-09 |
| 20110136740 | CYSTINE KNOT PEPTIDES BINDING TO ALPHA IIb BETA 3 INTEGRINS AND METHODS OF USE - Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against α | 2011-06-09 |
| 20110136741 | DICARBA-ANALOGUES OF OCTREOTIDE - Analogues of octreotide, their preparation and use are described. | 2011-06-09 |
| 20110136742 | ANTIDEPRESSANT PRODRUGS - The invention provides antidepressant prodrugs comprising an antidepressant conjugated to one or more amino acids. The invention also relates to pharmaceutical compositions comprising an antidepressant prodrug, and to methods of preparing and using the same. | 2011-06-09 |
| 20110136743 | Survivin, a protein that inhibits cellular apoptosis, and its modulation - The present invention provides the amino acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the Survivin family of proteins, methods for identifying agents that block Survivin mediated inhibition of cellular apoptosis, methods of using agents that block Survivin mediated inhibition or Survivin expression to modulate biological and pathological processes, and methods of assaying Survivin activity. | 2011-06-09 |
| 20110136744 | CYCLOSPORIN ANALOG FORMULATIONS - The present disclosure relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations. | 2011-06-09 |
| 20110136745 | METHOD OF SELECTING SOYBEANS WITH ENHANCED BIOACTIVITY AND COMPOSITIONS FOR REDUCING CANCER CELL VIABILITY - The invention provides a method that uses enzyme-treatment of whole soybeans or partially defatted soybeans to select soybeans with improved bioactivity or bioactivities. The invention further provides a soybean plant and seed with a non-transgenic mutation conferring enhanced bioactivity as an hydrolysate when compared to hydrolysate from other seeds, for instance in a cell-based assay, including reduced cancer cell viability; increased LDL receptor activity; reduced lipid accumulation; increased adiponectin expression; decreased FAS and LPL expression; reduced production of NO and PGE | 2011-06-09 |
| 20110136746 | Kallikrein-Binding "Kunitz Domain" Proteins and Analogues Thereof - This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides. | 2011-06-09 |
| 20110136747 | USE OF TIGHT JUNCTION ANTAGONISTS TO TREAT INFLAMMATORY BOWL DISEASE - The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents. | 2011-06-09 |
| 20110136748 | NOVEL GLUCOPYRANOSE DERIVATIVES, PREPARATION THEREOF, AND BIOLOGICAL USES THEREOF - The invention relates to a novel ester, the 3,5-di-tertiobutyl-4-hydroxybenzoate of 3,4,5-trihydroxy-6-methoxytetrahydropyran-2-yl methyl defined by the following formula (I). The invention also relates to the method for preparing the compound of formula (I) and to the use of said compound (I) to prepare a drug for treating and/or preventing enveloped virus infections. | 2011-06-09 |
| 20110136749 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS - As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease. | 2011-06-09 |
| 20110136750 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS - As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease. | 2011-06-09 |
| 20110136751 | Use of Polyphenols in the Treatment of Cancer - The present invention relates to polyphenol compounds, compositions thereof, and methods for treating or preventing cancer in a subject, the methods comprising co-administering to a subject an effective amount of two or more polyphenol compounds or a polyphenol composition thereof. | 2011-06-09 |
| 20110136752 | NOVEL ANTIBIOTICS - The invention relates generally to novel antibiotics and their analogs, to processes for the preparation of these novel antibiotics, to pharmaceutical compositions comprising the novel antibiotics; and to methods of using the novel antibiotics to treat or inhibit various disorders. | 2011-06-09 |
| 20110136753 | GLYCOSYLATED INDOLECARBAZOLES, METHOD FOR OBTAINING SAME AND USES THEREOF - Glycosylated indolocarbazoles, method for obtaining same and uses thereof. This invention relates to rebeccamycin and staurosporine derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and the production of rebeccamycin and staurosporine derivatives. The invention also relates to bacterial strains that are of use for the production of rebeccamycin and staurosporine derivatives. Lastly, the rebeccamycin and staurosporine derivatives described herein are applicable to the field of human health, specifically for manufacturing drugs that are of use in the treatment of tumour, neurological and inflammatory diseases. | 2011-06-09 |
| 20110136754 | NOVEL TRIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS - The present invention relates to novel compounds of formula (A): | 2011-06-09 |
| 20110136755 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY - The invention provides compounds having the following general formula (I): | 2011-06-09 |
| 20110136756 | COMBINATION ANTITUMOR THERAPY - The present disclosure relates to methods of treating cancers that are responsive to antimetabolite or antimitotic anti-cancer agents. The methods involve the use of at least one anti-cancer agent selected from antimetabolite anti-cancer agents, antimitotic anti-cancer agents, and combinations thereof, and a superoxide dismutase mimetic to potentiate the therapeutic effect of the anti cancer agent(s). | 2011-06-09 |
| 20110136757 | HYPERSULFATED DISACCHARIDE FORMULATIONS - Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof. | 2011-06-09 |
| 20110136758 | CARBOHYDRATE COMPOSITIONS FROM BASIDIOMYCETE FUNGI AS BIOCIDAL AGENTS ACTIVE AGAINST PATHOGENS - The invention provides biologically active compositions comprising oligosaccharides, and which are produced by growing a fungal culture, and are at least partially purified for use. The compositions of the invention have antibacterial, antifungal and nematicidal activity, and are thus useful to reduce the impact of such pathogens on growing plants, to reduce the occurrence of such pathogens on surfaces and in substances, and to treat infections caused by such pathogens in animals and humans. The invention also provides methods for producing such compositions from certain fungal cultures. | 2011-06-09 |
| 20110136759 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin analogs may be prepared synthetically, biosynthetically, or semi-synthetically. The analogs are particularly useful in treating or preventing infections caused by Gram-positive organisms. Certain inventive compounds may have a broader spectrum of coverage, which includes Gram-negative organisms. | 2011-06-09 |
| 20110136760 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases - The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww. | 2011-06-09 |
| 20110136761 | Vapour of a Citrus Essential Oil Blend and Its Antimicrobial Properties - A vapour of a blend comprising the oil of orange and the oil of bergamot, a process for its preparation and its use as an antimicrobial. The vapour has been found to be particularly useful on food contaminated with microorganisms without affecting the sensory properties of the food. | 2011-06-09 |
| 20110136762 | FUNGICIDAL PYRIDAZINES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, | 2011-06-09 |
| 20110136763 | TRISUBSTITUTED BORON-CONTAINING MOLECULES - This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections. | 2011-06-09 |
| 20110136764 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS - Compounds of Formula 1, as shown below and defined herein: | 2011-06-09 |
| 20110136765 | Pyrrolo[2,3-D]Pyrimidine Compounds - Described herein are pyrrolo[2,3-d]pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing these compounds, and methods for their preparation. | 2011-06-09 |
| 20110136766 | AURORA KINASE INHIBITORS - Disclosed herein are Aurora kinase Inhibitors represented by Structural Formula (I): Values for the variables in Structural Formula (I) are defined herein. | 2011-06-09 |
| 20110136767 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF - A series of monoquarternary piperazium salts including a structure of a formula I or II are provided. In formula I or II, R | 2011-06-09 |
| 20110136768 | IMATINIB MESYLATE FOR THE TREATMENT OF NEPHROGENIC SYSTEMIC FIBROSIS - Disclosed herein are methods of treatment and/or prevention of nephrogenic systemic fibrosis (NSF) in a subject in need thereof. The methods comprise administering an effective amount of imatinib mesylate to the subject, to thereby treat or prevent the nephrogenic systemic fibrosis. A corticosteroid and/or an antihistamine may also be administered. In one embodiment, the subject has chronic kidney disease, and/or is undergoing hemodialysis, and/or is in renal failure, and/or has been exposed to gadolinium such as gadolinium-containing contrast. The subject may also undergo an additional therapy to treat or prevent nephrogenic systemic fibrosis, chronic kidney disease, or renal failure, such as extracorporeal photopheresis, or administration of pentoxyphyline. Administration may be systemic, such as oral. Useful doses are from about 200 mg-600 mg, a day. Also disclosed are pharmaceutical compositions comprising imatinib mesylate and a pharmaceutically acceptable carrier, optionally formulated for oral administration. | 2011-06-09 |
| 20110136769 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR - A method of treating Alzheimer's disease, Parkinson's disease, sexual dysfunction or erectile dysfunction in a man by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile dysfunction, including PDE V inhibitors; AGE (advanced glycation end-product) breakers; alpha 1 blockers; alpha 1A antagonists; alpha 2 antagonists; dopamine agonists; dopamine D4 agonists; melanocortin agonists; oxytocin agonists; prostaglandin; radical scavengers; rotamase inhibitors; aviptadil; nitroglycerine; and GPCR agonists for treating male sexual dysfunction or erectile dysfunction. | 2011-06-09 |
| 20110136770 | Method for Providing Emergency Contraception - The invention provides a method for providing emergency contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate in an oral dosage form before, during or after a meal. | 2011-06-09 |
| 20110136771 | Orally Disintegrating Solid Dosage Forms Comprising Progestin and Methods of Making and Use Thereof - The present invention is directed to non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising progestin and methods of making and using the dosage forms to treat conditions in females in need thereof. | 2011-06-09 |
| 20110136772 | SUGAR COATINGS AND METHODS THEREFOR - Compositions particularly useful as coatings for solid dosage forms of therapeutic agents are provided, as are solid dosage forms comprising such coatings, processes for preparing such solid dosage forms, and the products of those processes. The coating compositions generally provide excellent strength and resistance to cracking, even when applied to flexible/swellable tablet cores such as hydrogel-type cores. The compositions also exhibit excellent odor-blocking characteristics. | 2011-06-09 |
| 20110136773 | Pharmaceutical Uses of Lanosta-8,24-dien-3-ols - The invention generally refers to pharmaceutical uses of lanosta-8,24-dien-3-ols, a family of tetracyclic terpenols, as anti-inflammatory, anticancerigenous and analgesic agents via the inhibition of the disordered activation of serine-threonine protein kinases, particularly PKC. | 2011-06-09 |
| 20110136774 | Anti-Apoptotic Benzodiazepine Receptor Ligand Inhibitors - The present invention provides low molecular weight porphyrin compositions for inhibiting, preventing or delaying the binding of a ligand of a mitochondrial benzodiazepine receptor. The invention also provides pharmaceutical compositions comprising these porphyrin compositions and their use in the treatment of conditions involving the mitochondrial benzodiazepine receptor or interactions between the receptor and the mitochondrial permeability transition pore e.g., drug overdose or apoptosis including neural degeneration and radiation-induced apoptosis. | 2011-06-09 |
| 20110136775 | Methods for Treating Injury Associated with Exposure to an Alkylating Species - Compounds may be administered to prevent or rescue organ injury following exposure to alkylating agents, such as sulfur mustards. The compounds may be substituted metalloporphyrins. | 2011-06-09 |
| 20110136776 | Copper(1)Chloride Complex of Nicotinic Acid and Pharmaceutical Compositions Containing the Same - Copper (I) chloride complex of nicotinic acid and pharmaceutical compositions containing the same. Such pharmaceutical composition are effective for the treatment of myopathy, myasthenia gravis, parkinsonism, Chronic Fatigue Syndrome, Male Infertility and post stroke muscle weakness, muscular dystrophy, skin burns, scars, alopecia, high blood lipids and obesity. | 2011-06-09 |
| 20110136777 | CRYSTALLINE SODIUM SALT OF CEPHALOSPORIN ANTIBIOTIC - Polymorphs of Ceftiofur sodium as a crystalline product and a process for the preparation of polymorphs of crystalline Ceftiofur sodium of formula (I). | 2011-06-09 |
| 20110136778 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF - A compound of the following general formula [I]: | 2011-06-09 |
| 20110136779 | METHODS FOR STROKE REDUCTION IN ATRIAL FIBRILLATION PATIENTS - The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering a multiple ion channel blocker anti-arrhythmic to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of multiple ion channel blocker and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of the multiple ion channel blocker may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling. In some methods of the invention, budiodarone is administered 400 mg BID or more preferably 600 mg BID. | 2011-06-09 |
| 20110136780 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK - Disclosed are JAK inhibitors of formula I | 2011-06-09 |
| 20110136781 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS - The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. | 2011-06-09 |
| 20110136782 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL USE - The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I) and salt thereof (wherein, R | 2011-06-09 |
| 20110136783 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: | 2011-06-09 |
| 20110136784 | Method of Treating Anxiety Disorders - A method of treating at least one symptom or condition associated with but not limited to: Anxiety Disorders including but not limited to Panic Disorder Without Agoraphobia, Panic Disorder With Agoraphobia, Agoraphobia Without History of Panic Disorder, Specific Phobia, Social Phobia, Obsessive-Compulsive Disorder, Postaumatic Stress Disorder, Acute Stress Disorder, Generalized Anxiety Disorder and Generalized Anxiety Disorder Due to a General Medical Condition comprising administering an effective amount of Formula I | 2011-06-09 |
| 20110136785 | METHOD OF TREATMENT - A method of treating at least one symptom or condition associated with but not limited to: 1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative-, Hypnotic- or Anxiolytic-Related Disorders. 2) Attention-Deficit and Disruptive Behavior Disorders. 3) Eating Disorders. 4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. 5) Impulse-Control Disorders, comprising administering an effective amount of Formula I | 2011-06-09 |
| 20110136786 | METHOD OF TREATING MOOD DISORDERS - Methods of treating mood disorders comprising administering an effective amount of 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof and pharmaceutical compositions therefor. | 2011-06-09 |
| 20110136787 | DIPHENYL AZEPANE, DIAZEPANE AND OXAZEPANE DERIVATIVES AND USES THEREOF - Compounds of the formula I: | 2011-06-09 |
| 20110136788 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME - [Problem] The present invention aims to provide an agent for the prophylaxis or treatment of irritable bowel syndrome. | 2011-06-09 |
| 20110136789 | C-MET PROTEIN KINASE INHIBITORS - The present invention relates to compounds of formula I useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative disorders. | 2011-06-09 |
| 20110136790 | Tricyclic Heterocyclic Derivatives and Methods of Use - The present invention relates to novel Tricyclic Heterocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Heterocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. R1 is formula (Ia), (Ib) or (Ic); R | 2011-06-09 |
| 20110136791 | COMBINATION OF A NICOTINIC RECEPTOR PARTIAL AGONIST AND OF AN ACETYLCHOLINESTERASE INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF IN THE TREATMENT OF COGNITIVE DISORDERS - The combination of an alpha-7 nicotinic receptor agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition comprising the combination and the use thereof in the treatment of cognitive disorders. | 2011-06-09 |
| 20110136792 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS - Provided herein are compounds of the formula (I): | 2011-06-09 |
| 20110136793 | AMELIORATING DRUG-INDUCED ELEVATIONS IN BLOOD PRESSURE BY ADJUNCTIVE USE OF ANTIHYPERTENSIVE DRUGS - Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are atrisk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies. | 2011-06-09 |
